Emergent BioSolutions

Emergent BioSolutions Inventory

The Inventory of Emergent BioSolutions (EBS) as of Oct 20, 2026 is 343.40 M USD. In the previous year, Inventory was 311.70 M USD — a change of 10.17% (higher).

Inventory

343.40 MUSD

YoY

10.17%

Last updated:

Inventory of Emergent BioSolutions is 2025 343.40 M USD. Inventory of Emergent BioSolutions was 2024 311.70 M USD. It decreases by 10.17% higher compared to the previous year.

The Emergent BioSolutions Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
205.80 M USD
Jan 1, 2019
222.50 M USD
Jan 1, 2020
307.00 M USD
Jan 1, 2021
344.50 M USD
Jan 1, 2022
350.70 M USD
Jan 1, 2023
328.90 M USD
Jan 1, 2024
311.70 M USD
Jan 1, 2025
343.40 M USD
The Emergent BioSolutions Inventory history
YEARInventoryYoY
343.40 MUSD+10.17%
311.70 MUSD-5.23%
328.90 MUSD-6.22%
350.70 MUSD+1.80%
344.50 MUSD+12.21%
307.00 MUSD+37.98%
222.50 MUSD+8.11%
205.80 MUSD+44.11%
142.81 MUSD+92.98%
74.00 MUSD-3.81%
76.94 MUSD+17.15%
65.67 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Emergent BioSolutions Stock analysis

What does Emergent BioSolutions do? Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Emergent BioSolutions stock

Inventory of Emergent BioSolutions is 343.40 M USD in 2025.

Inventory of Emergent BioSolutions changed from 311.70 M USD to 343.40 M USD, representing a 10.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Emergent BioSolutions since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Emergent BioSolutions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Emergent BioSolutions

All Key Metrics — Emergent BioSolutions